c-LEcta, a world-leading biotechnology company focused on enzyme engineering and applications in regulated markets like food and pharma, has closed a financing round with Capricorn Venture Partners and the German investment company bm|t. The capital increase, advised by Carlsquare, provides the company with growth capital as well as valuable access to an international network.
Kevin Reeder, CEO of bm|t added, “bm|t, which has a substantial life sciences portfolio, is very optimistic about its investment in c-LEcta. The company´s strong team, track record of successful development, and a highly compelling product pipeline were extremely impressive. We feel c-LEcta is well-positioned to transition to a high-value biotechnology product company.”
| Industry: | Life Science |
| Assignment: | Sell-side |
